House lawmakers voted Wednesday to approve a bill that would let terminally ill patients request access to experimental drugs that are under consideration by the FDA and have undergone early-stage clinical trials. The "right-to-try" legislation now heads to the Senate, which unanimously passed a different version of the bill last year.
One lot of Free-Range Chicken and one lot of Free-Range Turkey Recipe cat food, both of Rad Cat Raw Diet brand, were recalled by Radagast Pet Food because they tested positive for Listeria monocytogenes contamination. The recalled chicken products, which have the lot number 62762 and a best-by date of Oct. 19, were shipped to distributors in six states, and turkey products, with the lot number 62926 and a best-by date of May 3, 2019, were sold through independent pet retail stores in 10 states.
Smith & Nephew reached an agreement with Fort Worth, Texas, to invest $29 million in the expansion of its facilities in the city -- a move that is expected to create 100 jobs -- and has also received a $730,000 grant from the Texas Enterprise Fund as part of the expansion. The city, which houses the US headquarters for the company's Advanced Wound Management business, competed with three other locations for the project and agreed to impose a 55% cut on the company's city tax bill.
The NIH has been working with more than 30 drugmakers to develop alternatives to addictive opioid pain drugs as scientists learn more about the neurobiology of pain, NIH Director Francis Collins said. A House Energy and Commerce Committee subcommittee is also considering a proposal to encourage research on new nonaddictive pain drugs.
Sun Pharmaceutical Industries' Ilumya, or tildrakizumab-asmn, was approved by the FDA to treat adult patients with moderate to severe plaque psoriasis who are eligible for phototherapy or systemic therapy.
Fennec Pharmaceuticals' Pedmark, or sodium thiosulfate, which is being developed as a treatment for cisplatin-related ototoxicity in pediatric patients with standard-risk hepatoblastoma, was given fast-track review status by the FDA.
Eiger BioPharmaceuticals will move forward with its single registration study to evaluate the efficacy of its hepatitis D candidate lonafarnib after receiving approval from the FDA. The trial will involve 300 participants with hepatitis D virus infection who will be treated with either a combination of lonafarnib and ritonavir or lonafarnib, ritonavir and pegylated interferon-alfa compared with placebo.
The first-in-human implants of the combination therapy Ventouch Triad device, involving two patients with severe type IIIb functional mitral valve regurgitation with heart dilation and impaired left ventricle function, ware recorded by Mardil Medical in Paraguay. The device is intended for treating the dilated ventricle and affected valve in patients with functional mitral valve regurgitation.
The Dornier Medilas H Solvo 35, a holmium laser designed for treating urinary stones, was launched in Europe by Dornier MedTech. The laser, which builds on the company's Solvo 30, comes with a patented advanced mode for reduced stone movement in lithotripsy.
A round of Series B financing brought in an untranched $125 million for TCR2 Therapeutics. The company plans to launch an early-stage study of TC-210 for solid tumors this year and file a new-drug application for a second program by 2019.
- Page 1